Search Results
Your search for The matches 34643 pages
Showing 21901 - 21950Expert Point of View: Virginia Kaklamani, MD, and Melinda L. Telli, MD
Moderator of the press conference on this study, Virginia Kaklamani, MD, of the University of Texas Health Science Center at San Antonio, agreed that an improvement in response is important. “If you are a patient with symptoms, such as a cough from lung metastases, and I give you a combination...
Veliparib Improves Reponse but Not Progression-Free Survival in BRCA-Mutation Carriers
A randomized phase II study in women with metastatic breast cancer who have mutations in BRCA1 or BRCA2 evaluated the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to combination chemotherapy. The trial did not meet its primary endpoint.1 Hyo Sook Han, MD, of Moffitt...
Randomized Trial Demonstrates Benefit of Scalp-Cooling in Prevention of Chemotherapy-Induced Hair Loss
A scalp-cooling device was found safe and effective in preventing chemotherapy-induced hair loss in women undergoing adjuvant treatment for breast cancer in an interim analysis of the first prospective, randomized trial of a modern scalp-cooling system. The study was presented at the 2016 San...
Expert Point of View: Melinda L. Telli, MD
Melinda L. Telli, MD, Assistant Professor of Medicine at Stanford University Medical Center, Palo Alto, commented on this topic for The ASCO Post. She said the results of the two studies reinforce what has been emerging about the prognostic impact of tumor-infiltrating lymphocytes. “We have known...
ECCO 2017: Pembrolizumab Shows Activity in Mucosal Melanoma in Multiple KEYNOTE Studies
Three clinical trials of the immunotherapy pembrolizumab (Keytruda) have shown that it is active against a rare subtype of skin cancer, mucosal melanoma. The findings were presented by Butler et al at the 2017 European Cancer Congress (ECCO) (Abstract 1142). Until now, mucosal melanoma has often...
Potential Suboptimal Use of Guideline-Endorsed Genomic Testing in Non–Small Cell Lung and Colorectal Cancers
In a study reported in the Journal of Oncology Practice, Gray et al found that many medical oncologists did not use genomic testing endorsed by guidelines in place in 2012 and 2013 in patients with non–small cell lung cancer (NSCLC) and colorectal cancer. The study involved a survey of U.S....
Adjuvant Letrozole vs Anastrozole in Hormone Receptor–Positive Node-Positive Early Breast Cancer
As reported in the Journal of Clinical Oncology by Smith et al, the final results of the phase III FACE trial showed no difference in disease-free or overall survival for adjuvant letrozole vs anastrozole in postmenopausal women with hormone receptor–positive node-positive early breast...
FDA Approves Nivolumab in Locally Advanced or Metastatic Bladder Cancer
On February 2, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have...
Tumor-Infiltrating Lymphocytes Prognostic in the Metastatic and Neoadjuvant Breast Cancer Settings
Studies presented at the 2016 San Antonio Breast Cancer Symposium added to growing evidence that tumor-infiltrating lymphocytes are important prognostic factors in breast cancer. One investigation evaluated their impact in advanced HER2-positive breast cancer, finding a linear relationship between...
Expert Point of View: Heinz-Josef Lenz, MD
Heinz-Josef Lenz, MD, of the University of Southern California in Los Angeles, said the results of the ONO-4538 trial were impressive in light of this challenging patient population. “You see a significant benefit in a highly refractory gastric cancer population,” he said. Dr. Lenz cautioned:...
Nivolumab, as Salvage, Improves Overall Survival in Gastric Cancer
Gastric cancer can apparently be added to the growing list of malignancies for which drugs targeting the programmed cell death protein 1 (PD‑1) receptor are effective, according to the results of the phase III ONO-4538 investigation conducted in Asia and presented at the 2017 Gastrointestinal...
The Cost of a Patient’s Last Ride
It was a call from a referring physician who wanted the patient to be transferred to our major academic center. The patient had a history of a lethal malignancy in a very advanced stage. The patient was already outside the bell curve, for she had survived far longer than expected for a malignancy...
FDA Establishes Oncology Center of Excellence, Names Richard Pazdur, MD, Director
On January 19, 2017, U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, MD, issued the following statement: Today the U.S. Food and Drug Administration is establishing the Oncology Center of Excellence and appointing Richard Pazdur, MD, as its Director. This will make oncology...
Expert Point of View: Frank A. Sinicrope, MD
Frank A. Sinicrope, MD, Professor of Medicine and Oncology at the Mayo Clinic, Rochester, Minnesota, told The ASCO Post that the regimen of irinotecan/cetuximab (Erbitux)/vemurafenib (Zelboraf) could be an important approach to treating this challenging tumor subtype. “BRAF-mutated tumors have a...
Dual Inhibition Proves Effective for BRAF-Mutated Colorectal Tumors
In patients with metastatic colorectal cancer who have mutations in BRAF V600, the addition of the BRAF inhibitor vemurafenib (Zelboraf) to cetuximab (Erbitux) and irinotecan significantly improved progression-free survival, results of the phase II Southwest Oncology Group (SWOG) 1406 trial have...
IASLC Statement on Philip Morris’ New Manifesto Highlights the Importance of Tobacco Control
On February 1, 2017, the International Association for the Study of Lung Cancer (IASLC) issued the following statement: “According to its own public reports, in 2016 Phillip Morris manufactured 800 billion cigarettes. Thus, [IASLC] views with some skepticism Philip Morris’ recent...
ECCO 2017: Melanoma Death Rates Will Fall by 2050, but Number of Deaths Will Increase
By 2050, the death rates from malignant melanoma will have decreased from their current levels, but the numbers of people dying from the disease will have increased due to the aging of populations. However, if new treatments for the deadly skin cancer prove to be effective, the numbers of deaths...
ECCO 2017: Breath Test Might Help Detect Stomach and Esophageal Cancers
A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the esophagus and stomach in a large patient trial presented by Markar et al at the 2017 European Cancer Congress (Abstract 6LBA). Together, stomach and esophageal...
Intermittent Sunitinib Appears Feasible in Previously Untreated Metastatic Renal Cell Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Ornstein et al found that an intermittent schedule of sunitinib (Sutent) may be feasible in patients with previously untreated metastatic renal cell carcinoma. Study Details In the study, 37 patients with clear cell metastatic...
Phase III Trial Finds First-Line Ceritinib Improves PFS vs Platinum-Based Chemotherapy in ALK-Rearranged NSCLC
In a phase III trial (ASCEND-4) reported in The Lancet, Soria et al found that ceritinib (Zykadia) improved progression-free survival vs platinum-based chemotherapy in first-line treatment of advanced ALK-rearranged non–small cell lung cancer (NSCLC). Ceritinib is a next-generation selective...
ASH/AACR/AACI/ASTRO/ASPHO/Lungevity Foundation Statement on Administration's Executive Order
Today, the American Society of Hematology, the American Association for Cancer Research, the Association of American Cancer Institutes, the American Society for Radiation Oncology, the American Society of Pediatric Hematology/Oncology, and the LUNGevity Foundation issued a statement on the...
Postmenopausal Normal-Weight Women With Poor Metabolic Health May Have Higher Risk for Colorectal Cancer
Few studies have explored the association between metabolic phenotype and colorectal cancer incidence in normal-weight individuals. Now, a study comparing the risk of colorectal cancer in normal-weight postmenopausal women with a metabolically unhealthy phenotype vs those with a metabolically...
Immunotherapy 2.0 Named Advance of the Year in ASCO's Report
A growing number of patients with cancer are benefiting from research advances in immunotherapy, leading ASCO to name immunotherapy as the Society's Advance of the Year for a second year in a row. Released today, Clinical Cancer Advances 2017: ASCO's Annual Report on Progress Against Cancer...
Benefits of Multiparametric Magnetic Resonance Imaging in Clinically Significant Prostate Cancer
In the UK PROMIS study reported in The Lancet, Ahmed et al found that use of multiparametric magnetic resonance imaging (MP-MRI) might reduce the need for transrectal ultrasound (TRUS)-guided prostate biopsy and may improve detection of clinically significant prostate cancer. Study Details In the ...
ASCO Clinical Practice Guideline on Management of Small Renal Masses
As reported in the Journal of Clinical Oncology by Antonio Finelli, MD, of Princess Margaret Cancer Centre, Toronto, and colleagues, ASCO has released a clinical practice guideline on management of small renal masses. The guideline was derived from an expert panel literature search for and...
How Does Sublingual Fentanyl Measure Up Against Subcutaneous Morphine in Managing Cancer Pain?
An Italian single-center trial compared treatment with sublingual fentanyl tablets and subcutaneous morphine in managing severe pain episodes in cancer patients receiving opioid treatment. In the Journal of Clinical Oncology, Zecca et al reported that the trial did not show noninferiority of...
Study Finds Addition of Adjuvant Capecitabine to Gemcitabine Improves Survival in Resected Pancreatic Cancer
In the European phase III ESPAC-4 trial reported in The Lancet, Neoptolemos et al found that adding adjuvant capecitabine to gemcitabine significantly improved overall survival in patients with resected pancreatic cancer. Study Details In the open-label trial, 730 patients from 92 hospitals in...
Arti Hurria, MD, on Senior Citizens: Living Through and Beyond Cancer
Arti Hurria, MD, of City of Hope, discusses the assessment of older patients with cancer.
Angela R. Bradbury, MD, on Genetic Information and Clinical Care
Angela R. Bradbury, MD, of the University of Pennsylvania, discusses genetic testing, tumor profiling, and the identification of those at increased risk for second cancers.
Allison Harvey, MPH, CHES, on Teaching Providers About Survivorship
Allison Harvey, MPH, CHES, of George Washington University, evaluates preliminary outcomes among primary care and oncology providers who took part in the Cancer Survivorship E-Learning Series (Abstract 78).
Shoshana M. Rosenberg, ScD, MPH, on Young Breast Cancer Survivors: Helping Them Cope
Shoshana M. Rosenberg, ScD, MPH, of the Dana-Farber Cancer Institute, talks about ways to help young women move from active treatment to survivorship, based on findings from focus groups in which patients discussed their unexpected physical and psychological experiences after surgery (Abstract 180).
Lauren P. Wallner, PhD, MPH, on Breast Cancer Survivorship Care: Patient Preferences
Lauren P. Wallner, PhD, MPH, of the University of Michigan, discusses her findings on the type of providers women prefer when it comes to handling survivorship care after breast cancer treatment and the need to clarify and discuss provider roles with patients (Abstract 99).
Sophia Kustas Smith, PhD, MSW, on Depression and Fatigue: Self-Managed in 'Reimagine'
Sophia Kustas Smith, PhD, MSW, of Duke University, discusses study findings on an online, symptom self-management curriculum, known as www.reimagine.me, employed for breast cancer survivors with chronic pain (Abstract 182).
Electra D. Paskett, PhD, on Preventing Lymphedema: Results of a CALGB Study
Electra D. Paskett, PhD, of The Ohio State University Comprehensive Cancer Center, discusses an intervention that increased knowledge of lymphedema in breast cancer, and the personal story that drove her research (Abstract 104).
Ann H. Partridge, MD, MPH, on Adolescent and Young Adult Patients: Their Survivorship Challenges
Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute, summarizes a session she co-chaired on the unique issues affecting adolescent and young adult patients, including their psychosocial needs and concerns that clinicians may overlook.
Dong Wook Shin, MD, DrPH, MBA, on Thyroid Cancer: Risk of Side Effects
Dong Wook Shin, MD, DrPH, MBA, of Seoul National University Cancer Hospital, discusses the risk of coronary heart disease and ischemic stroke in patients with thyroid cancer taking levothyroxine (Abstract 105).
Mohammad Abu Zaid, MD, on Testicular Cancer: Study Results on Metabolic Syndrome
Mohammad Abu Zaid, MD, of Indiana University Simon Cancer Center, discusses findings from a multicenter study of North American testicular cancer survivors, their prevalence of hypertension, risk factors for metabolic syndrome, and the need for screening and treatment (Abstract 102).
Emily S. Tonorezos, MD, on Childhood Cancer Survivors and Late-Occurring Effects
Emily S. Tonorezos, MD, of Memorial Sloan Kettering Cancer Center, discusses childhood cancer survivors and the protection from late-occurring anthracycline-related cardiotoxicity conferred by a RARG coding variant.
K. Holly Mead, PhD, on Identifying Models of Cancer Survivorship Care
K. Holly Mead, PhD, of George Washington University, discusses specialized survivorship-specific programs, which are gaining prominence, with over 40% of cancer centers in her study providing this type of care (Abstract 1).
Shawna V. Hudson, PhD, on Breast Cancer: A Quality-of-Life Program
Shawna V. Hudson, PhD, of Rutgers University, discusses a survivorship program designed to improve the quality of life for Hispanic and Latino breast cancer survivors (Abstract 183).
ECCO 2017: Some Patients With Early-Stage Breast Cancer May Benefit More From Breast-Conserving Therapy Than Mastectomy
Breast-conserving therapy (breast-conserving surgery combined with radiation therapy) may be superior to mastectomy in certain patients with breast cancer, according to results from the largest study on this topic to date, presented at the 2017 European Cancer Congress (Abstract 4LBA). Although...
ECCO 2017: Low Cause-Specific Mortality in Women Over 50 Treated for Ductal Carcinoma in Situ
Women over 50 who have been treated for ductal carcinoma in situ (DCIS) are more likely to be alive 10 years later than women in the general population, according to new research presented by Elshof et al at the 2017 European Cancer Congress (ECCO) (Abstract 173). DCIS differs from breast cancer...
High Financial Burden for CML Patients Enrolled in Medicare Part D Receiving Targeted Oral Therapy
In a study reported in the Journal of Oncology Practice, Shen et al found that more than three-quarters of patients receiving targeted oral therapy for chronic myeloid leukemia (CML) reached the catastrophic phase of the Medicare Part D benefit within the calendar year of starting such treatment....
Trends in Cancer Mortality in the United States and U.S. Counties From 1980 to 2014
In a study reported in JAMA, Mokdad et al found that cancer mortality rates have dropped from 240.2 to 192.0/100,000 population between 1980 and 2014. Mortality rates varied widely among U.S. counties for various cancers. The report covers 29 cancers in 3,144 counties. Summarized here are findings...
Small-Intestine GIST Treated Surgically Associated With Better Prognosis in Younger Patients
Gastrointestinal stromal tumors (GIST) arise is the wall of the digestive tract and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can occur in adolescents and young adults (AYA) under 40 years old as well. In an article published by Fero et al in...
Diagnosis and Management of AML in Adults: 2017 European LeukemiaNet Recommendations From an International Expert Panel
An international panel of experts has released updated evidence-based and expert opinion–based recommendations for the diagnosis and treatment of acute myeloid leukemia (AML) in adults. The recommendations were issued by the European LeukemiaNet (ELN) and published by Döhner et al in...
Health-Related Quality of Life After Cancer Diagnosis in Adolescents/Young Adults
In a longitudinal study reported in the Journal of Clinical Oncology, Husson et al found that health-related quality of life improved between diagnosis and 2 years after diagnosis in adolescent/young adult (AYA) patients with cancer, but it remained impaired compared with population norms. Study...
Predicting Acute Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy
In a Dutch study reported in the Journal of Clinical Oncology, van den Bogaard et al found that a model including the volume of the left ventricle receiving 5 Gy (LV-V5) might provide improved prediction of acute cardiac events in patients with breast cancer receiving radiotherapy. Prior findings...
Three Genetic Alterations Identified in Non–Down Syndrome Pediatric Acute Megakaryoblastic Leukemia
Research led by St. Jude Children’s Research Hospital has identified three genetic alterations to help identify high-risk pediatric patients with acute megakaryoblastic leukemia (AMKL) who may benefit from allogeneic stem cell transplants. The study, published by de Rooij et al in Nature...
ECCO 2017: Twice-Daily Radiation Therapy May Reduce Mortality in Head and Neck Cancer
Treating patients with head and neck cancer with hyperfractionated twice-daily radiation therapy combined with chemotherapy could potentially reduce mortality, according to new research presented by Petit et al at the 2017 European Cancer Congress (ECCO) (Abstract 823). The study, led by Claire...
